VCYT logo

Veracyte Inc. (VCYT)

$24.23

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VCYT

Market cap

$1.96B

EPS

1.54

P/E ratio

32.3

Price to sales

6.47

Dividend yield

--

Beta

1.978

Price on VCYT

Previous close

$24.01

Today's open

$23.99

Day's range

$23.60 - $24.47

52 week range

$21.91 - $60.91

Profile about VCYT

CEO

Marc Stapley

Employees

755

Headquarters

South San Francisco, CA

Exchange

NASDAQ Global Market

Shares outstanding

80695480

Issue type

Common Stock

VCYT industries and sectors

Healthcare

Medical Diagnostics & Screening

News on VCYT

Artisan Global Discovery Fund Q3 2026 Portfolio Activity

During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. In addition to Twilio, West Pharmaceutical and RBC Bearings, we added to Neptune Insurance, Lattice Semiconductor and Cognex during the quarter. In addition to Modine Manufacturing, we ended our investment campaigns in Monolithic Power Systems and Tradeweb Markets.

news source

Seeking Alpha • 8 hours ago

news preview

Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky

Needham reportedly cut its Veracyte price target by $23 per share after the Company's November 4, 2026 outlook reset on its Decipher Prostate test. An investigation into potential securities law violations is underway on behalf of VCYT shareholders who lost money.

news source

PRNewsWire • Nov 12, 2026

news preview

Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo

Veracyte is rated Hold, as its valuation premium has vanished, but growth prospects have weakened, especially for Decipher prostate cancer testing. Decipher's test volume growth is slowing sharply, with management now planning for a 40% lower annual increase versus prior years. VCYT trades at 2.87x forward sales and 12.95x earnings, below sector medians, yet consensus expects a 19.38% EPS decline in 2027.

news source

Seeking Alpha • Nov 12, 2026

news preview

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)

Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk Veracyte's third-quarter report said Decipher Prostate volume came in below the Company's expectations, and full-year 2026 revenue guidance was narrowed as Decipher's annual volume projections were slashed. The investigation concerns potential securities law violations tied to Decipher Prostate growth risk

news source

GlobeNewsWire • Nov 10, 2026

news preview

Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript

Veracyte, Inc. ( VCYT ) 2026 UBS Global Healthcare Conference November 10, 2026 4:15 PM EST Company Participants Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good afternoon.

news source

Seeking Alpha • Nov 11, 2026

news preview

VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $VCYT--VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law.

news source

Business Wire • Nov 9, 2026

news preview

VCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte

Veracyte shares fell after its November 4, 2026 report despite $151.8 million in third-quarter revenue and a new $100 million buyback, as the market reacted to a weaker Decipher Prostate outlook. An investigation concerns potential securities law violations.

news source

PRNewsWire • Nov 6, 2026

news preview

Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment

VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Veracyte Crashes Almost 40% On Seismic Shift For Its Best-Selling Test

Veracyte stock crashed almost 40% early Thursday after the company reset growth expectations for its prostate cancer tissue test, Decipher.

news source

Investors Business Daily • Nov 5, 2026

news preview

What Veracyte (VCYT) Said on Its Q3 Earnings Call

Veracyte NASDAQ: VCYT reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management's forecast. The company also outlined a preliminary 2027 outlook for mid-single-digit revenue growth as it invests in its commercial teams and expands its cancer testing portfolio.

news source

MarketBeat • Nov 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Veracyte Inc.

Open an M1 investment account to buy and sell Veracyte Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VCYT on M1